Subconjunctival dexamethasone implant (Ozurdex^®) in the management of refractory Non-Infectious anterior scleritis.

IF 2.9 Q1 OPHTHALMOLOGY

Journal of Ophthalmic Inflammation and Infection Pub Date : 2025-05-06 DOI:10.1186/s12348-025-00494-6

Battuya Ganbold, Ba Trung Nguyen, Jia-Horung Hung, Azadeh Mobasserian, Zheng Xian Thng, Hashem Ghoraba, Negin Yavari, Dalia El Feky, Cigdem Yasar, Aim-On Saengsirinavin, Xiaoyan Zhang, Frances Andrea Anover, S Saeed Mohammadi, Ngoc Tuong, Trong Than, Anadi Khatri, Osama Elaraby, Amir Akhavanrezayat, Ankur Sudhir Gupta, Woong Sun Yoo, Quan Dong Nguyen, Christopher Or

{"title":"Subconjunctival dexamethasone implant (Ozurdex®) in the management of refractory Non-Infectious anterior scleritis.","authors":"Battuya Ganbold, Ba Trung Nguyen, Jia-Horung Hung, Azadeh Mobasserian, Zheng Xian Thng, Hashem Ghoraba, Negin Yavari, Dalia El Feky, Cigdem Yasar, Aim-On Saengsirinavin, Xiaoyan Zhang, Frances Andrea Anover, S Saeed Mohammadi, Ngoc Tuong, Trong Than, Anadi Khatri, Osama Elaraby, Amir Akhavanrezayat, Ankur Sudhir Gupta, Woong Sun Yoo, Quan Dong Nguyen, Christopher Or","doi":"10.1186/s12348-025-00494-6","DOIUrl":null,"url":null,"abstract":"Objective: To report a case series of non-infectious anterior scleritis resistant to multiple lines of conventional therapies which were eventually successfully treated with off-label subconjunctival dexamethasone implant (Ozurdex®) injection (SDI).Methods: A retrospective case series of 4 patients (6 eyes).Results: In the index case series, the patients had a mean age of 57.2 years (range 36 to 82 years, SD 19.2 years) with 50% being female. Two patients had underlying autoimmune diseases: rheumatoid arthritis (n = 1), and granulomatosis with polyangiitis (GPA) (n = 1). The other patients were diagnosed with idiopathic anterior scleritis after extensive systemic investigations (n = 2). The mean follow-up duration and the mean number of concomitant therapies prior to SDI was 27 (SD 17.7) months and 2 (SD 0.81), respectively. In all patients, symptom resolution and significant improvement in disease activity were achieved after SDI, persisting for an extended period following the resorption of the implant. No scleral melt, infection or ocular hypertension were noted following SDI.Conclusion: SDI may be a safe and effective therapeutic option for resistant non-infectious anterior scleritis.","PeriodicalId":16600,"journal":{"name":"Journal of Ophthalmic Inflammation and Infection","volume":"15 1","pages":"40"},"PeriodicalIF":2.9000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12055680/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ophthalmic Inflammation and Infection","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12348-025-00494-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To report a case series of non-infectious anterior scleritis resistant to multiple lines of conventional therapies which were eventually successfully treated with off-label subconjunctival dexamethasone implant (Ozurdex^®) injection (SDI).

Methods: A retrospective case series of 4 patients (6 eyes).

Results: In the index case series, the patients had a mean age of 57.2 years (range 36 to 82 years, SD 19.2 years) with 50% being female. Two patients had underlying autoimmune diseases: rheumatoid arthritis (n = 1), and granulomatosis with polyangiitis (GPA) (n = 1). The other patients were diagnosed with idiopathic anterior scleritis after extensive systemic investigations (n = 2). The mean follow-up duration and the mean number of concomitant therapies prior to SDI was 27 (SD 17.7) months and 2 (SD 0.81), respectively. In all patients, symptom resolution and significant improvement in disease activity were achieved after SDI, persisting for an extended period following the resorption of the implant. No scleral melt, infection or ocular hypertension were noted following SDI.

Conclusion: SDI may be a safe and effective therapeutic option for resistant non-infectious anterior scleritis.

查看原文本刊更多论文

结膜下地塞米松种植体（Ozurdex®）治疗难治性非感染性前巩膜炎

目的：报道一系列非感染性前巩膜炎对多种常规疗法产生耐药性的病例，最终成功地使用超说明书结膜下地塞米松植入物（Ozurdex®）注射（SDI）治疗。方法：对4例患者（6眼）进行回顾性分析。结果：在索引病例系列中，患者平均年龄为57.2岁（范围36 ~ 82岁，SD 19.2岁），其中50%为女性。2例患者有潜在的自身免疫性疾病：类风湿关节炎（n = 1）和肉芽肿病合并多血管炎（n = 1）。其他患者在广泛的全身检查后被诊断为特发性前巩膜炎（n = 2）。SDI前的平均随访时间和平均伴随治疗次数分别为27个月（SD 17.7）和2个月（SD 0.81）。在所有患者中，SDI后症状缓解和疾病活动度显著改善，并在种植体吸收后持续较长时间。SDI术后未见巩膜融化、感染或高眼压。结论：SDI可能是一种安全有效的治疗顽固性非感染性前巩膜炎的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊